BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 18812547)

  • 1. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution.
    Chlebowski RT; Prentice RL
    J Natl Cancer Inst; 2008 Oct; 100(19):1341-3. PubMed ID: 18812547
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Jan; 119(2):463-74. PubMed ID: 19424794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
    MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
    Breast Cancer Res Treat; 2010 Apr; 120(3):727-36. PubMed ID: 19672706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
    Eisen A; Lubinski J; Gronwald J; Moller P; Lynch HT; Klijn J; Kim-Sing C; Neuhausen SL; Gilbert L; Ghadirian P; Manoukian S; Rennert G; Friedman E; Isaacs C; Rosen E; Rosen B; Daly M; Sun P; Narod SA;
    J Natl Cancer Inst; 2008 Oct; 100(19):1361-7. PubMed ID: 18812548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
    Eisinger F; Huiart L
    J Natl Cancer Inst; 2009 Feb; 101(4):277; author reply 277-8. PubMed ID: 19211447
    [No Abstract]   [Full Text] [Related]  

  • 6. [Postmenopausal hormone therapy--an update. Benefit versus risk--important to identify women with increased breast cancer risk].
    von Schoultz B
    Lakartidningen; 2009 Aug 19-25; 106(34):2041-2. PubMed ID: 19769143
    [No Abstract]   [Full Text] [Related]  

  • 7. Postmenopausal hormone therapy and breast cancer.
    Prescrire Int; 2009 Apr; 18(100):66-7. PubMed ID: 19585723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of hormone therapy influences breast cancer risk.
    Harv Womens Health Watch; 2011 Apr; 18(8):7. PubMed ID: 21544975
    [No Abstract]   [Full Text] [Related]  

  • 9. Estrogen-progestin increases breast cancer risk.
    Stephens MB
    J Fam Pract; 2000 Apr; 49(4):301-2. PubMed ID: 10778832
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Kuller LH
    J Natl Cancer Inst; 2000 Jul; 92(13):1100-1. PubMed ID: 10880556
    [No Abstract]   [Full Text] [Related]  

  • 11. Do risks of hormone therapy persist after discontinuation?
    J Fam Pract; 2008 Jun; 57(6):366, 369. PubMed ID: 18677802
    [No Abstract]   [Full Text] [Related]  

  • 12. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.
    Speroff L
    Menopause; 2008; 15(2):393-400. PubMed ID: 17925662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oestrogens and progestins and breast cancer risk in post-menopausal women.
    La Vecchia C
    Pharmacol Res; 1995 Dec; 32(6):323-4. PubMed ID: 8736479
    [No Abstract]   [Full Text] [Related]  

  • 14. Breast cancer: the role of hormone therapy.
    Creasman WT
    Semin Reprod Med; 2005 May; 23(2):167-71. PubMed ID: 15852202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hormone replacement therapy in postmenopausal women and breast cancer risk: impact of estrogens deprivation and timing hypothesis].
    Brettes JP; Mathelin C
    Gynecol Obstet Fertil; 2007 Nov; 35(11):1092-4. PubMed ID: 17996474
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
    Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk.
    Rebbeck TR; Troxel AB; Shatalova EG; Blanchard R; Norman S; Bunin G; Demichele A; Schinnar R; Berlin JA; Strom BL
    Cancer Epidemiol Biomarkers Prev; 2007 Jun; 16(6):1318-20. PubMed ID: 17548708
    [No Abstract]   [Full Text] [Related]  

  • 18. Landmark hormone replacement therapy study stopped after finding more harms than benefits.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Aug; 13(15):5-7. PubMed ID: 12553323
    [No Abstract]   [Full Text] [Related]  

  • 19. Is combined estrogen/progestogen hormone therapy worth the risk?
    Sturdee DW; MacLennan AH
    Climacteric; 2003 Sep; 6(3):177-9. PubMed ID: 14567764
    [No Abstract]   [Full Text] [Related]  

  • 20. [Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)?].
    Ringa V; Fournier A
    Rev Epidemiol Sante Publique; 2008 Oct; 56(5):297-301. PubMed ID: 18947946
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.